Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer

Globo H (GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant combination, we chemically synthesized and linked GH to a carrier protein, including keyhole limpet hemocyanion, diphtheria toxoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant, and it was administered to mice for the study of immune response. Glycan microarray analysis of the antiserum obtained indicated that the combination of GH-DT adjuvanted with the α-galactosylceramide C34 has the highest enhancement of anti-GH IgG. Compared with the phase III clinical trial vaccine, GH–keyhole limpet hemocyanion/QS21, the GH-DT/C34 vaccine elicited more IgG antibodies, which are more selective for GH and the GH-related epitopes, stage-specific embryonic antigen 3 (SSEA3) and SSEA4, all of which were specifically overexpressed on breast cancer cells and breast cancer stem cells with SSEA4 at the highest level (>90%). We, therefore, further developed SSEA4-DT/C34 as a vaccine candidate, and after immunization, it was found that the elicited antibodies are also IgG-dominant and very specific for SSEA4.

[1]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides , 1997, International journal of cancer.

[2]  S. Ménard,et al.  Study of the expression and function of the tumour-associated antigen CaMBr1 in small cell lung carcinomas. , 1993, European Journal of Cancer.

[3]  S. Hakomori,et al.  Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. , 1984, The Journal of biological chemistry.

[4]  King-Jen Chang,et al.  Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers , 2009, PloS one.

[5]  Chi-Huey Wong,et al.  Synthesis of the Globo H Hexasaccharide Using the Programmable Reactivity-Based One-Pot Strategy. , 2001 .

[6]  Chung-Yi Wu,et al.  Highly alpha-selective sialyl phosphate donors for efficient preparation of natural sialosides. , 2010, Chemistry.

[7]  S. Ménard,et al.  Prognostic significance of the CaMBr1 antigen on breast carcinoma: relevance of the type of recognised glycoconjugate. , 1993, European journal of cancer.

[8]  L. Kaer,et al.  Lipid antigen presentation in the immune system; lessons learned from CD 1 d knockout mice , 1999, Immunological reviews.

[9]  L. Norton,et al.  Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Canevari,et al.  Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. , 1983, Cancer research.

[11]  D. Solter,et al.  New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. , 1983, The Journal of biological chemistry.

[12]  D. Ho,et al.  Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. , 2006, Journal of the American Chemical Society.

[13]  Larry Norton,et al.  Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Ménard,et al.  Reactivity of a monoclonal antibody with tissues and tumors from the human breast. Immunohistochemical localization of a new antigen and clinicopathologic correlations. , 1984, The American journal of pathology.

[15]  S. Muller,et al.  Effect of Skin Barrier Disruption on Immune Responses to Topically Applied Cross-Reacting Material, CRM197, of Diphtheria Toxin , 2005, Infection and Immunity.

[16]  P. Chapman,et al.  Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Gabius,et al.  Biological Information Transfer Beyond the Genetic Code: The Sugar Code , 2000, Naturwissenschaften.

[18]  I. Wilson,et al.  Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Jyh‐cherng Yu,et al.  Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis , 2008, Proceedings of the National Academy of Sciences.

[20]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[21]  R. Rappuoli,et al.  Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine , 2008, Infection and Immunity.

[22]  M. Kronenberg,et al.  Mouse CD1 is mainly expressed on hemopoietic-derived cells. , 1997, Journal of immunology.

[23]  Zachary Shriver,et al.  Glycomics: a pathway to a class of new and improved therapeutics , 2004, Nature Reviews Drug Discovery.

[24]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[25]  Chi-Huey Wong,et al.  Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN , 2008, Proceedings of the National Academy of Sciences.

[26]  V. Reuter,et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  H. Scher,et al.  A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. , 1999, Angewandte Chemie.

[28]  Y. Koezuka,et al.  KRN7000, a novel immunomodulator, and its antitumor activities. , 1995, Oncology research.

[29]  D. A. Thayer,et al.  Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Robbins,et al.  Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. , 1969, Biochemistry.

[31]  G. Turner.  N-glycosylation of serum proteins in disease and its investigation using lectins. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[32]  Mitchell Kronenberg,et al.  Constitutive Cytokine mRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function , 2003, The Journal of experimental medicine.

[33]  S. Ménard,et al.  Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. , 1983, Cancer research.

[34]  C. Kensil,et al.  Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. , 1994, Vaccine.

[35]  E. Osinaga,et al.  Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. , 1991, British Journal of Cancer.

[36]  S. Hakomori,et al.  Glycosphingolipid antigens and cancer therapy. , 1997, Chemistry & biology.

[37]  M. Kronenberg,et al.  Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. , 1998, Journal of immunology.

[38]  R. Rappuoli,et al.  Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin , 2001, Infection and Immunity.

[39]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[40]  Chung-Yi Wu,et al.  Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer , 2008, Proceedings of the National Academy of Sciences.

[41]  H. Scher,et al.  Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Danishefsky,et al.  Immunization of Mice with a Fully Synthetic Globo H Antigen Results in Antibodies against Human Cancer Cells: A Combined Chemical—Immunological Approach to the Fashioning of an Anticancer Vaccine , 1997 .

[43]  D. Bundle,et al.  A new homobifunctional p-nitro phenyl ester coupling reagent for the preparation of neoglycoproteins. , 2004, Organic letters.

[44]  T. Natori,et al.  Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. , 1995, Journal of medicinal chemistry.

[45]  M. Kronenberg,et al.  Selective Ability of Mouse CD1 to Present Glycolipids: α-Galactosylceramide Specifically Stimulates Vα14+ NK T Lymphocytes , 1998, The Journal of Immunology.

[46]  A. Iasonos,et al.  Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer , 2007, Clinical Cancer Research.

[47]  D. Bundle,et al.  Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology. , 2005, The Journal of organic chemistry.

[48]  Y. Koezuka,et al.  Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. , 1996, Oncology research.